Open the Gate – My Disclosure: The Dark Side of Clinical Trials Episode 4

(caution)

These pictures are copyright protected by 2026, Medical enhance co, ltd and Kico Aizaki,

Dear readers,

I am Kico Aizaki

This post is a continuation of my previous blog post.


I talked to three detectives from the security intelligence police department regarding the flow of money in clinical trials.

They asked me the same question: "Why is there a distinction between disclosed obligation money and non-disclosed obligation money?"

I answered that cooperating medical institutions, SMOs (Site Management Organizations), and IRBs (Institutional Review Boards) must disclose payments from pharmaceutical companies based on the contracts between the pharmaceutical company and each institution.

However, CROs (Contract Research Organizations) and CRAs (Clinical Research Associates) have no duty to disclose payment amounts from pharmaceutical companies.

CROs work with many vendors, academic doctors, and suppliers. Furthermore, CROs and CRAs do not disclose the detailed breakdown of payments made to these companies or doctors.

These actual incurred costs are called "development costs for clinical trials," which include expenditures from non-clinical animal studies up to Phase I through Phase III human clinical trials.

These development costs are used as an index to decide new drug prices after a new drug is approved by the Ministry of Health, Labour and Welfare (MHLW).

Pharmaceutical companies negotiate new drug prices to cover their development costs and earn a profit exceeding those actual costs during the drug's patent period.

And in addition, Ⅰhad to explain about that why the pharmaceutical company rejected the audit by the Ministry of Health, Labour and Welf

To be continued…
(caution)
These pictures are copyright protected by 2026, Medical enhance co, ltd and Kico Aizaki,

The copyrights and image rights of the contents of this site (text, photographs, images, data, pictures, graphics, etc.) and their arrangement, editing and structure are owned by Kiko Aizaki and Medical Enhance Co. (except some) Unauthorized use (including reproduction, transmission, broadcast, publication, distribution, posting, transfer, loan, translation, adaptation, licensing, re-use, etc. of all or part of the website), reprinting, modification, falsification, commercial Please refrain from using it for commercial purposes.

Messages les plus consultés de ce blogue

A Happy New Year, we have started to celebrate the lead up to 2026!

The Amazing and Mysterious Story of Togakushi-Shrine in Nagano Prefecture.

The Issue, Why does Injustice Occurs in Industry?